Riociguat information

Riociguat
Clinical data
Trade names	Adempas
Other names	BAY 63-2521
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Pregnancy; category	AU: X (High risk); ;
Routes of; administration	By mouth
ATC code	C02KX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	94%
Protein binding	95%
Metabolism	CYP1A1, CYP3A4, CYP2C8, CYP2J2
Metabolites	N-desmethylriociguat (active), glucuronide (inactive)
Elimination half-life	12 h (patients); 7 h (healthy people)
Excretion	33–45% via kidney,; 48–59% via bile duct
Identifiers
	IUPAC name Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate;
CAS Number	625115-55-1 ;
IUPHAR/BPS	5257;
DrugBank	DB08931 ;
ChemSpider	9479719 ;
UNII	RU3FE2Y4XI;
KEGG	D09572 ;
ChEBI	CHEBI:76018 ;
CompTox Dashboard (EPA)	DTXSID50978109 ;
ECHA InfoCard	100.169.606
Chemical and physical data
Formula	C20H19FN8O2
Molar mass	422.424 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c14ncccc4c(-c(nc2N)nc(N)c2N(C)C(=O)OC)nn1Cc3ccccc3F;
	InChI InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26) ; Key:WXXSNCNJFUAIDG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylate cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators.^[4] The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.

It is available as a generic medication.^[5]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ Cite error: The named reference Drugs.com was invoked but never defined (see the help page).
^ "Background Riociguat". Bayer HealthCare. Archived from the original on 18 July 2011. Retrieved 15 December 2009.
^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[2] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[Drugs.com-3] Cite error: The named reference Drugs.com was invoked but never defined (see the help page).

[TS2-4] "Background Riociguat". Bayer HealthCare. Archived from the original on 18 July 2011. Retrieved 15 December 2009.

[5] "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

Riociguat information

and 29 Related for: Riociguat information

Riociguat

Nitrate

Sildenafil

Pulmonary hypertension

Soluble guanylate cyclase stimulator

Bayer

Nitroglycerin

Nitric oxide

ATC code C02

Amyl nitrite

Isosorbide dinitrate

Arginine

PDE5 inhibitor

Isosorbide mononitrate

Metal nitrosyl complex

Nitrite

Alkyl nitrite

Sodium nitroprusside

Calcium in biology

Cinaciguat

Nitrosamine

Exhaled nitric oxide

Vericiguat

Cyclic guanosine monophosphate

Nicorandil

Pentamidine

Guanosine triphosphate

Pentaerythritol tetranitrate

Nitric oxide synthase